New study went head-to-head with HA vs. HA spiked with a little PRP magic. Spoiler alert: both help with pain.

PER-001, delivered through a slow-release, dissolvable implant in the vitreous cavity of the eye, is designed to block ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Re-Vana Therapeutics is collaborating with Boehringer Ingelheim to develop extended-release therapies for ophthalmic diseases ...

Medicare only covers PRP injections to treat nonhealing diabetic wounds. The treatment period must meet specific criteria and not exceed 20 weeks.

Plasma therapy is one of several different experimental longevity procedures that involve blood transfers, including platelet-rich plasma treatment, which concentrates and injects a patient’s ...

Ocugen's drug to treat retina diseases received a rare pediatric disease designation from U.S. regulators. The biotechnology said Tuesday that the Food and Drug Administration granted the ...

Biotech Atsena eye disease gene therapy hits safety goals, closes retinal splits in phase 1/2 By Darren Incorvaia May 19, 2025 12:59pm Atsena Therapeutics Cell & Gene Therapy eye disease retina ...

Opus Genetics announces upcoming presentations on gene therapy research for inherited retinal diseases at May 2025 conferences.

Johnson & Johnson’s gene therapy for X-linked retinal pigmentosa did not meet the main vision goal of a pivotal study. J&J secured full rights to the program from gene therapy biotech MeiraGTx ...

Odylia Therapeutics Announces New Pipeline Project: A Gene Replacement Therapy for NPHP1 Retinal Dystrophy PR Newswire ATLANTA, May 5, 2025 ...